Phase 2 N=148 Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer
Neutropenia
Primary: Duration of Severe Neutropenia (DSN) in Cycle 1 — 1.03; 0.44; 0.03; 0.31 days — p=0.296
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=76 Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma
Intraocular Melanoma · Melanoma (Skin)
Primary: Percentage of Participants With Immune-related Adverse Events (irAEs) — 80.0; 72.0; 65.4 Percentage of participants
Phase 2 N=100 A Study of IMR-687 in Adult Participants With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia)
Sickle Cell Disease
Primary: Number Of Participants With Treatment-emergent Adverse Events (TEAEs) And Serious Adverse Events (SAEs) — 12; 24; 18; 23 Participants
Phase 2 N=11 PolyPEPI1018 Vaccine and CDx for the Treatment of Metastatic Colorectal Cancer (OBERTO)
Colorectal Cancer
Primary: Number of Participants With Treatment Related Adverse Events — 0; 0 Participants
Phase 2 N=170 High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant
Hematopoietic Cell Transplantation Recipient · Malignant Neoplasm · Influenza
Primary: Immunogenicity as Measured by the Number of Subjects Who Achieve a 4-fold (or Greater) Rise in Post-vaccination HAI Titers — 0.20; 0.20; 0.42; 0.31 proportion of…
Phase 2 N=75 Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma
Stage IIIC Melanoma · Stage IV Melanoma
Primary: Percentage of Participants With Immune-related Overall Response Rate (irORR) — 9.5; 3.1 percentage of participants
Phase 2 N=272 Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Primary: Objective Response Rate, Defined as the Percentage of Subjects With a Best Overall Response of Confirmed Complete Response (CR) or Partial Response (PR) — 69.3; 64.0…
Phase 2 N=7 A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531
Waldenstrom Macroglobulinemia
Primary: Overall Response Rate (ORR) of Carfilzomib in Bortezomib naïve and Bortezomib-exposed Relapsed WM — 85.7 percentage of participants
Phase 2 N=165 A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer
Carcinoma · Non-Squamous Non-Small-Cell Lung Cancer
Primary: Tumor Response Rate (RR) — 0; 0; 0; 0 percentage of participants — p==0.384
Phase 2 N=73 Niclosamide for Mild to Moderate COVID-19
COVID-19
Primary: Time to Respiratory Viral Clearance — 3.39; 3.44 Days
Phase 2 N=200 A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis
Psoriasis
Primary: • The Percent Change in PASI (Psoriasis Area and Severity Index) Score From Baseline — -38.1; -48.2; -50.7; -25.0 percentage change from baseline — p=0.066
Phase 2 N=14 Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis With Polyposis Nasi
Rhinosinusitis · Chronic Polyposis
Primary: Change of Inflammation of the Nasal Mucosa and Paranasal Sinus — -2; -0.8 units on a scale
Phase 2 N=10 Histopathology Following CCH Injection
Characteristics of Subcutaneous Tissue
Primary: Number of Participants With a Histologic Change in a Tissue Specimen That Was Injected With CCH — 2; 1; 1; 2 Participants
Phase 2 N=19 Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis
Rhinosinusitis
Primary: Change of Inflammation of the Nasal Mucosa and Paranasal Sinus — 0; -0.8 score on a scale
Phase 2 N=21 Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers
Carcinoma, Non-Small -Cell Lung · Ovarian Neoplasms · Small Cell Lung Carcinoma
Primary: Ph I: Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) of Topotecan — 1.25 mg/m^2